HLB's Riboceranib + Camrelizumab Shows Consistent Efficacy Across Ages in CARES-310 uHCC Trial
In the global Phase 3 CARES-310 study, HLB's riboceranib‑camrelizumab combo achieved a median overall survival of 21.5 months in patients under 50, outperforming sorafenib's 15.2 months, with consistent benefit across age groups.